Pfizer expands Ibrance into HER2-positive breast cancer with first CDK4/6 maintenance win

Edited by Robert McTiernan··2 min read

The US FDA approved Ibrance (palbociclib) for a new indication in HR-positive, HER2-positive metastatic breast cancer, marking Pfizer’s first regulatory success for the CDK4/6 inhibitor in the HER2-positive setting. The approval covers maintenance treatment in adults following induction chemotherapy with a taxane and trastuzumab, with or without pertuzumab — a population that had lacked an established CDK4/6-based maintenance option.

Palbociclib is indicated at 125 mg orally once daily on a 21-days-on, 7-days-off schedule within a 28-day cycle, administered alongside trastuzumab, with or without pertuzumab, and endocrine therapy — either fulvestrant or an aromatase inhibitor. The approval carries warnings for neutropenia, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. Palbociclib received Breakthrough Therapy Designation for this indication.

Efficacy was evaluated in the PATINA trial (NCT02947685), a randomized, open-label Phase III study enrolling 518 patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer who had no evidence of progression after induction treatment. Patients were randomized 1:1 to palbociclib plus trastuzumab, with or without pertuzumab, and endocrine therapy, or to the anti-HER2 and endocrine therapy backbone alone. The primary endpoint of investigator-assessed progression-free survival (PFS) per RECIST 1.1 demonstrated a statistically significant improvement, with a hazard ratio of 0.76 (95% CI: 0.59–0.97; one-sided p=0.0134). Median PFS could not be fully characterized due to censoring, and overall survival data remained immature at the time of the PFS analysis.

The AllSci BriefSystematic R&D and deal news. Daily.

Palbociclib selectively inhibits cyclin-dependent kinases 4 and 6, blocking cell cycle progression from G1 to S phase and suppressing tumor cell proliferation. The rationale for combining CDK4/6 inhibition with HER2-directed therapy rests on evidence that HER2 signaling can drive cyclin D1 expression, potentially rendering HR-positive, HER2-positive tumors susceptible to CDK4/6 blockade — a mechanistic premise that PATINA’s PFS benefit appears to support.

The approval extends palbociclib’s established role in HR-positive, HER2-negative metastatic breast cancer into a distinct molecular subtype. CDK4/6 inhibitors ribociclib (Kisqali, Novartis) and abemaciclib (Verzenio, Eli Lilly) dominate the HER2-negative HR-positive space, but neither holds an approved indication in HER2-positive maintenance. This positions palbociclib as the first CDK4/6 inhibitor approved specifically for the HR-positive, HER2-positive maintenance setting, adding to a competitive landscape where anti-HER2 regimens have historically defined the standard of care.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/